This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have upgraded their ratings for several companies, including Nike, Alcoa, Outset Medical, Freeport-McMoRan, and Prestige Consumer Healthcare. These upgrades come with increased price targets, indicating a bullish outlook for these stocks.
June 21, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley upgraded Alcoa from Equal-Weight to Overweight and raised the price target from $36.5 to $50. Alcoa shares gained 4% to close at $38.98.
The upgrade to Overweight and the significant increase in the price target indicate strong positive sentiment, likely driving short-term price appreciation for Alcoa.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Morgan Stanley upgraded Freeport-McMoRan from Equal-Weight to Overweight and raised the price target from $49.5 to $62. Shares gained 3.5% to close at $49.36.
The upgrade to Overweight and the increased price target indicate strong positive sentiment, likely leading to short-term price appreciation for Freeport-McMoRan.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Oppenheimer upgraded Nike from Perform to Outperform and raised the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57.
The upgrade from Perform to Outperform and the increased price target suggest a positive outlook for Nike, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
RBC Capital upgraded Outset Medical from Sector Perform to Outperform and raised the price target from $5 to $6. Despite the upgrade, shares fell 1.5% to $3.5850.
The upgrade to Outperform and the increased price target suggest a positive outlook, but the recent price drop indicates mixed investor sentiment. Short-term impact may be positive as the market digests the upgrade.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
DA Davidson upgraded Prestige Consumer Healthcare from Neutral to Buy and raised the price target from $65 to $93. Shares settled at $65.28.
The upgrade to Buy and the significant increase in the price target suggest a strong positive outlook, likely driving short-term price appreciation for Prestige Consumer Healthcare.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100